Advertisement
Screener

X4 PHARMACEUTICALS, INC (XFOR) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1.7 / 5 stars · 14/42 Roast Me

X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 767.28 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06

  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 682.63K shares, a 1639.14% increase year-over-year.
  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 84.65K shares, a 4.77% increase year-over-year.
  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 907.53K shares, a 118.50% increase year-over-year.
  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 79.01K shares, a 59.38% decline year-over-year.
  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.11M shares, a 1.90% increase from fiscal 2024.
  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.09M shares.
  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 228.56K shares, a 32.91% decline from fiscal 2021.
  • X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 340.65K shares, a 26.43% increase from fiscal 2020.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed
2026-06-30682.63K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
767.28K shares
10-Q · filed 2026-08-06
1.67M shares
derived: sum of 3 quarters · filed 2026-08-06
1.75M shares
derived: sum of 4 quarters · filed 2026-08-06
2026-03-3184.65K shares
10-Q · filed 2026-05-06
992.18K shares
derived: sum of 2 quarters · filed 2026-05-06
1.07M shares
derived: sum of 3 quarters · filed 2026-05-06
1.11M shares
derived: sum of 4 quarters · filed 2026-05-06
2025-12-31907.53K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17
986.53K shares
derived: sum of 2 quarters · filed 2026-03-17
1.03M shares
derived: sum of 3 quarters · filed 2026-03-17
1.11M shares
10-K · filed 2026-03-17
2025-09-3079.01K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
118.26K shares
derived: sum of 2 quarters · filed 2025-11-05
199.06K shares
10-Q · filed 2025-11-05
614.39K shares
derived: sum of 4 quarters · filed 2025-11-05
2025-06-3039.25K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08
120.05K shares
10-Q · filed 2025-08-08
535.39K shares
derived: sum of 3 quarters · filed 2025-08-08
729.91K shares
derived: sum of 4 quarters · filed 2025-08-08
2025-03-3180.80K shares
10-Q · filed 2025-05-01
496.14K shares
derived: sum of 2 quarters · filed 2025-05-01
690.66K shares
derived: sum of 3 quarters · filed 2025-05-01
853.61K shares
derived: sum of 4 quarters · filed 2025-05-01
2024-12-31415.34K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
609.86K shares
derived: sum of 2 quarters · filed 2025-03-26
772.81K shares
derived: sum of 3 quarters · filed 2025-03-26
1.09M shares
10-K · filed 2025-03-26
2024-09-30194.52K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
357.47K shares
derived: sum of 2 quarters · filed 2024-11-13
670.64K shares
10-Q · filed 2024-11-13
2024-06-30162.95K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
476.12K shares
10-Q · filed 2024-08-08
2024-03-31313.17K shares
10-Q · filed 2024-05-07
2023-09-3065.70K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
73.28K shares
derived: sum of 2 quarters · filed 2023-11-09
99.36K shares
10-Q · filed 2023-11-09
-84.41K shares
derived: sum of 4 quarters · filed 2024-03-21
2023-06-307.58K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
33.66K shares
10-Q · filed 2023-08-10
-150.11K shares
derived: sum of 3 quarters · filed 2024-03-21
25.27K shares
derived: sum of 4 quarters · filed 2024-03-21
2023-03-3126.08K shares
10-Q · filed 2023-05-04
-157.69K shares
derived: sum of 2 quarters · filed 2024-03-21
17.69K shares
derived: sum of 3 quarters · filed 2024-03-21
154.90K shares
derived: sum of 4 quarters · filed 2024-03-21
2022-12-31-183.77K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-8.39K shares
derived: sum of 2 quarters · filed 2024-03-21
128.81K shares
derived: sum of 3 quarters · filed 2024-03-21
228.56K shares
10-K · filed 2024-03-21
653.77K shares
10-K · filed 2023-03-21
2022-09-30175.38K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
312.58K shares
derived: sum of 2 quarters · filed 2022-11-03
412.33K shares
10-Q · filed 2022-11-03
500.47K shares
derived: sum of 4 quarters · filed 2022-11-03
2022-06-30137.21K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
236.95K shares
10-Q · filed 2022-08-04
325.09K shares
derived: sum of 3 quarters · filed 2022-08-04
365.92K shares
derived: sum of 4 quarters · filed 2022-08-04
2022-03-3199.74K shares
10-Q · filed 2022-05-12
187.88K shares
derived: sum of 2 quarters · filed 2022-05-12
228.72K shares
derived: sum of 3 quarters · filed 2022-05-12
332.92K shares
derived: sum of 4 quarters · filed 2022-05-12
2021-12-3188.14K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
128.97K shares
derived: sum of 2 quarters · filed 2022-03-17
233.18K shares
derived: sum of 3 quarters · filed 2022-03-17
340.65K shares
10-K · filed 2022-03-17
2021-09-3040.83K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
145.04K shares
derived: sum of 2 quarters · filed 2021-11-04
252.51K shares
10-Q · filed 2021-11-04
356.98K shares
derived: sum of 4 quarters · filed 2021-11-04
2021-06-30104.20K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03
211.68K shares
10-Q · filed 2021-08-03
316.14K shares
derived: sum of 3 quarters · filed 2021-08-03
345.42K shares
derived: sum of 4 quarters · filed 2021-08-03
2021-03-31107.47K shares
10-Q · filed 2021-05-06
211.94K shares
derived: sum of 2 quarters · filed 2021-05-06
241.21K shares
derived: sum of 3 quarters · filed 2021-05-06
354.32K shares
derived: sum of 4 quarters · filed 2021-05-06
2020-12-31104.46K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19
133.74K shares
derived: sum of 2 quarters · filed 2021-03-19
246.85K shares
derived: sum of 3 quarters · filed 2021-03-19
269.44K shares
10-K · filed 2021-03-19
2020-09-3029.27K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
142.38K shares
derived: sum of 2 quarters · filed 2020-11-05
164.98K shares
10-Q · filed 2020-11-05
220.55K shares
derived: sum of 4 quarters · filed 2020-11-05
2020-06-30113.11K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
135.71K shares
10-Q · filed 2020-08-04
191.28K shares
derived: sum of 3 quarters · filed 2020-08-04
288.98K shares
derived: sum of 4 quarters · filed 2020-08-04
2020-03-3122.59K shares
10-Q · filed 2020-05-07
78.17K shares
derived: sum of 2 quarters · filed 2020-05-07
175.87K shares
derived: sum of 3 quarters · filed 2020-05-07
309.84K shares
derived: sum of 4 quarters · filed 2020-05-07
2019-12-3155.57K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
153.27K shares
derived: sum of 2 quarters · filed 2020-03-12
287.25K shares
derived: sum of 3 quarters · filed 2020-03-12
309.63K shares
10-K · filed 2020-03-12
2019-09-3097.70K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
231.68K shares
derived: sum of 2 quarters · filed 2019-11-07
254.05K shares
10-Q · filed 2019-11-07
352.67K shares
derived: sum of 4 quarters · filed 2019-11-07
2019-06-30133.97K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
156.35K shares
10-Q · filed 2019-08-07
254.97K shares
derived: sum of 3 quarters · filed 2019-08-07
306.38K shares
derived: sum of 4 quarters · filed 2019-08-07
2019-03-3122.38K shares
10-Q · filed 2019-05-15
121.00K shares
derived: sum of 2 quarters · filed 2019-05-15
172.40K shares
derived: sum of 3 quarters · filed 2019-05-15
2018-12-3198.62K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11
150.03K shares
derived: sum of 2 quarters · filed 2019-03-11
262.00K shares
10-K · filed 2019-03-11
2018-09-3051.41K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
163.38K shares
10-Q · filed 2018-11-09
2018-06-30111.98K shares
10-Q · filed 2018-08-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Ocugen, Inc. (OCGN)United States$0.343B-6.34